Roche ex­pands its PhI­II pro­gram for Eylea ri­val as long-act­ing da­ta back its block­buster con­tender faricimab

Roche’s Genen­tech has notched an­oth­er suc­cess on its way to chal­leng­ing Re­gen­eron — as well as the oth­er Big Phar­ma con­tender No­var­tis — for the block­buster crown …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER